Literature DB >> 7634601

Methotrexate loaded acrylic cement in the management of skeletal metastases. Biomechanical, biological, and systemic effect.

H M Wang1, C S Galasko, S Crank, G Oliver, C A Ward.   

Abstract

Skeletal metastases occur commonly, and frequently are complicated by the development of an impending or pathologic fracture. In the majority of instances, these patients are best treated by internal stabilization, frequently supplemented by methylmethacrylate, to relieve pain and maintain the patient's mobility. The underlying tumor may continue to grow, and if this occurs the progressive lysis may result in loosening and subsequent failure of the implant. To prevent additional local growth, postoperative radiotherapy is recommended, and many patients also receive endocrine or chemotherapy, but the adjuvant therapy is not always successful in preventing progressive local tumor induced osteolysis. It is possible that the addition of chemotherapeutic agents to the methylmethacrylate may inhibit local growth. This study was performed to determine the biomechanical, biologic, and systemic effects of adding methotrexate to methylmethacrylate. The results show that the addition of methotrexate in as much as a concentration of 2 g methotrexate per 40 g cement did not significantly alter the biomechanical characteristics of the bone cement. The incorporated methotrexate was released continuously from the loaded bone cement, and in the amount and concentration used did not have any toxic effects on the host animal. The methotrexate did not appear to be affected by the heat of polymerization and had a significant systemic effect. There was a significant reduction in pulmonary metastases with methotrexate loaded cement as compared with unloaded cement, the effect being dependent on the concentration of methotrexate in the cement. The results of these studies indicate that methotrexate loaded cement may have an important role to play as part of the orthopaedic management of impending and pathologic fractures.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7634601

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  7 in total

Review 1.  Vertebroplasty for metastasis.

Authors:  Markus Wenger
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

2.  Effects of water-soluble component content on cephalexin release from bioactive bone cement consisting of bis-GMA/TEGDMA resin and bioactive glass ceramics.

Authors:  M Otsuka; M Sawada; Y Matsuda; T Nakamura; T Kokubo
Journal:  J Mater Sci Mater Med       Date:  1999-01       Impact factor: 3.896

3.  The use of fluoride cement: preliminary experimental study and clinical application.

Authors:  Claudia Di Bella; Enrico Lucarelli; Milena Fini; Roberto Giardino; Mario Mercuri; Davide Donati
Journal:  Chir Organi Mov       Date:  2008-05-21

4.  Methotrexate released in vitro from bone cement inhibits human stem cell proliferation in S/G2 phase.

Authors:  Egon Prochazka; Tomas Soukup; Milos Hroch; Leos Fuksa; Eva Brcakova; Jolana Cermanova; Gabriela Kolouchova; Karel Urban; Jaroslav Mokry; Stanislav Micuda
Journal:  Int Orthop       Date:  2009-02-11       Impact factor: 3.075

5.  Methotrexate-added acrylic cement: biological and physical properties.

Authors:  G Maccauro; A Cittadini; M Casarci; F Muratori; D De Angelis; C Piconi; M A Rosa; A Spadoni; M Braden; A Sgambato
Journal:  J Mater Sci Mater Med       Date:  2007-01-04       Impact factor: 4.727

Review 6.  Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review.

Authors:  Sunjeev S Phull; Alireza Rahimnejad Yazdi; Michelle Ghert; Mark R Towler
Journal:  J Bone Oncol       Date:  2020-12-16       Impact factor: 4.072

7.  Dual-functional porous and cisplatin-loaded polymethylmethacrylate cement for reconstruction of load-bearing bone defect kills bone tumor cells.

Authors:  Zhule Wang; Liebert Parreiras Nogueira; Håvard Jostein Haugen; Ingrid Cm Van Der Geest; Patricia Caetano de Almeida Rodrigues; Dennis Janssen; Thom Bitter; Jeroen J J P van den Beucken; Sander Cg Leeuwenburgh
Journal:  Bioact Mater       Date:  2021-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.